Eriksson E T, Schimmelpenning H, Rutqvist L E, Johansson H, Auer G U
Department of Tumour Pathology, Karolinska Institute and Hospital, Stockholm, Sweden.
Br J Cancer. 1993 Jun;67(6):1418-22. doi: 10.1038/bjc.1993.263.
Immunohistochemical expression of the tumour associated mucin-type glycoprotein A-80 was investigated in a series of 173 breast cancer patients with a clinical follow-up between 13 and 19 years. A routine immunoperoxidase technique was used in formalin-fixed, paraffin-embedded surgical tumour specimens. One hundred and fifty of 173 tumours (87%) immunostained with MAb A-80. The degree of A-80 immunoreactivity was related to the tumour grade but not to lymph node status, tumour size, or nuclear DNA distribution pattern. In univariate analysis the degree of A-80 expression was found to be of significant prognostic value both in node negative and in node positive breast cancer patients (P = 0.03). Patients with non-A-80 immunoreactive tumours had significant longer distant metastases-free survival times and fewer relapses than women with carcinomas composed of A-80 immunoreactive tumour cells. This prognostic value was reduced in a multivariate analysis, including lymph node status, tumour size, and nuclear DNA distribution pattern, but retained borderline significance (P = 0.08). In conclusion, the findings of this study indicate that expression of the mucin-type glycoprotein A-80 as determined by immunohistochemistry seems to be related to clinical outcome in breast cancer patients.
在173例乳腺癌患者中，对肿瘤相关粘蛋白型糖蛋白A - 80的免疫组化表达进行了研究，这些患者的临床随访时间为13至19年。采用常规免疫过氧化物酶技术，对福尔马林固定、石蜡包埋的手术肿瘤标本进行检测。173例肿瘤中有150例（87%）与单克隆抗体A - 80发生免疫染色。A - 80免疫反应性程度与肿瘤分级有关，但与淋巴结状态、肿瘤大小或核DNA分布模式无关。在单因素分析中，发现A - 80表达程度在淋巴结阴性和阳性的乳腺癌患者中均具有显著的预后价值（P = 0.03）。与由A - 80免疫反应性肿瘤细胞组成的癌患者相比，非A - 80免疫反应性肿瘤患者的无远处转移生存期显著更长，复发更少。在包括淋巴结状态、肿瘤大小和核DNA分布模式的多因素分析中，这种预后价值有所降低，但仍保留临界显著性（P = 0.08）。总之，本研究结果表明，免疫组化测定的粘蛋白型糖蛋白A - 80表达似乎与乳腺癌患者的临床结局相关。
